The ENVELOP Study will evaluate the safety and effectiveness of an investigational medication, called navitoclax, targeting cells that are not working normally in the blood and bone marrow. It is being evaluated in adults with chronic myelomonocytic leukaemia, polycythaemia vera, essential thrombocythaemia and myelofibrosis. The study will enrol about 47 participants across the United States and Europe. The study duration will vary from person to person depending on the response to the investigational medication.
Navitoclax has not been approved by regulatory agencies. Its safety and effectiveness are under evaluation. During this study, researchers continue to study the effectiveness of the investigational medication and monitor its side effects in a large group of study participants.